For citations:
Nekrasova K.A., Trofimov A.V., Zhahov A.V., Rodin S.V., Gorbunov N.P., Petrov A.V., Pigareva N.V., Alexandrov G.V., Zakharov M.S., Kiryanova A.S., Khuttunen O.E., Bendt I.V., Krylova A.E., Ischenko A.M. Preclinical Studies into Specific Toxicity of a Candidate Drug Based on Complement C3 neodeterminant Recombinant Humanized Antibody for Treating Traumatic Brain Injuries. Journal Biomed. 2021;17(4):68-80. (In Russ.) https://doi.org/10.33647/2074-5982-17-4-68-80